Trials / Unknown
UnknownNCT05801783
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Shanghai Yunying Medical Technology · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
10 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety, tolerability, and efficacy of the recombinant herpes simplex virus I, R130 in patients with relapsed/refractory ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant oncolytic herpes simplex virus type 1 (R130) | R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11 |
Timeline
- Start date
- 2022-12-02
- Primary completion
- 2024-12-02
- Completion
- 2025-12-02
- First posted
- 2023-04-06
- Last updated
- 2023-04-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05801783. Inclusion in this directory is not an endorsement.